.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A07E_IntestinalAntiinflammatoryAgents.A07EA04_Betamethasone.Betamethasone .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A07E_IntestinalAntiinflammatoryAgents.A07EA04_Betamethasone.Betamethasone| name: | Betamethasone |
| ATC code: | A07EA04 | route: | oral |
| n-compartments | 1 |
Betamethasone is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive effects. It is primarily used for the treatment of various inflammatory and autoimmune conditions, and is also used in the management of adrenal insufficiency. The A07EA04 ATC code refers specifically to its use as an intestinal anti-inflammatory/anti-infective agent. Betamethasone is approved for clinical use and is available in various formulations including oral, intravenous, intramuscular, and topical.
Pharmacokinetic parameters are estimated for healthy adults with oral administration, as no publication with direct PK parameters for betamethasone intestinal use (A07EA04) could be identified.
Krzyzanski, W, et al., & Jusko, WJ (2021). Population pharmacokinetic modeling of intramuscular and oral dexamethasone and betamethasone in Indian women. Journal of pharmacokinetics and pharmacodynamics 48(2) 261–272. DOI:10.1007/s10928-020-09730-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/33389521
Krzyzanski, W, et al., & Jusko, WJ (2021). Population pharmacodynamic modeling of intramuscular and oral dexamethasone and betamethasone effects on six biomarkers with circadian complexities in Indian women. Journal of pharmacokinetics and pharmacodynamics 48(3) 411–438. DOI:10.1007/s10928-021-09755-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/33954911
Lim, SY, et al., & Heard, CM (2020). Mucoadhesive thin films for the simultaneous delivery of microbicide and anti-inflammatory drugs in the treatment of periodontal diseases. International journal of pharmaceutics 573 118860–None. DOI:10.1016/j.ijpharm.2019.118860 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31759104